108

News

Genmab cancer medication in new promising showing

Christian Wenande
April 1st, 2016


This article is more than 8 years old.

Biotech form eyeing further approval of medication against multiple myeloma

Genmab results offer much potential (photo: Genmab)

The Danish biotech company Genmab is nearing a new victory in its battle against cancer following promising clinical results for Daratumumab, its medication against multiple myeloma, the most common type of bone marrow cancer.

Daratumumab, which is sold as Darzalex and has been approved only in the US as of now, fulfilled all of its goals in a considerable study during which the cancer returned after being treated by other medications.

“We are very pleased with the positive interim result in this study, which documents the therapeutic potential of daratumumab in combination with bortezomib and dexamethasone,” said Jan van de Winkel, the CEO of Genmab.

“We look forward to having the data presented at a future major medical conference.”

READ MORE: US authorities approve Danish cancer drug

Hoping for further approval
In total, daratumumab was administered to 490 patients along with either bortezomib, a type of chemotherapy, or dexamethason, another form of cancer treatment.

The results were so effective that the study was ended prematurely, which is something typically done if there is an effect that can save the lives of patients considered terminal.

Daratumumab is already approved for the treatment of patients with multiple myeloma who have undergone three previous treatments, but Genmab hopes the new study will help the medication to obtain approval for other treatment types.


Share

Most popular

Subscribe to our newsletter

Sign up to receive The Daily Post

















Latest Podcast

A survey carried out by Megafon for TV2 has found that 71 percent of parents have handed over children to daycare in spite of them being sick.

Moreover, 21 percent of those surveyed admitted to medicating their kids with paracetamol, such as Panodil, before sending them to school.

The FOLA parents’ organisation is shocked by the findings.

“I think it is absolutely crazy. It simply cannot be that a child goes to school sick and plays with lots of other children. Then we are faced with the fact that they will infect the whole institution,” said FOLA chair Signe Nielsen.

Pill pushers
At the Børnehuset daycare institution in Silkeborg a meeting was called where parents were implored not to bring their sick children to school.

At Børnehuset there are fears that parents prefer to pack their kids off with a pill without informing teachers.

“We occasionally have children who that they have had a pill for breakfast,” said headteacher Susanne Bødker. “You might think that it is a Panodil more than a vitamin pill, if it is a child who has just been sick, for example.”

Parents sick and tired
Parents, when confronted, often cite pressure at work as a reason for not being able to stay at home with their children.

Many declare that they simply cannot take another day off, as they are afraid of being fired.

Allan Randrup Thomsen, a professor of virology at KU, has heavily criticised the parents’ actions, describing the current situation as a “vicious circle”.

“It promotes the spread of viruses, and it adds momentum to a cycle where parents are pressured by high levels of sick-leave. If they then choose to send the children to daycare while they are still recovering, they keep the epidemic going in daycares, and this in turn puts a greater burden on the parents.”